[68Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?

[1] Mottet N(2017)EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent Eur Urol. 71 618-629

[2] Bellmunt J(2017)Therapy assessment in prostate cancer using choline and PSMA PET/CT Eur J Nucl Med Mol Imaging. 44 78-83

[3] Bolla M(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 45 228-247

[4] Briers E(2016)Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers Futur Oncol. 12 333-342

[5] Cumberbatch MG(2016)11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel Eur J Nucl Med Mol Imaging. 43 84-91

[6] De Santis M(2017)Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients Eur J Nucl Med Mol Imaging 44 1258-1268

[7] Ceci F(2018)Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls RadioGraphics. 38 200-217

[8] Herrmann K(2018)68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients Eur J Nucl Med Mol Imaging 45 2035-2044

[9] Hadaschik B(2019)Diagnostic performance of 68Ga-PSMA PET/CT in the detection of prostate cancer prior to initial biopsy: comparison with cancer-predicting nomograms Eur J Nucl Med Mol Imaging 46 908-920

[10] Castellucci P(2017)Oligometastases in prostate cancer Strahlentherapie und Onkologie 194 318-324

[1] Mottet N(2017)EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent Eur Urol. 71 618-629

[2] Bellmunt J(2017)Therapy assessment in prostate cancer using choline and PSMA PET/CT Eur J Nucl Med Mol Imaging. 44 78-83

[3] Bolla M(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 45 228-247

[4] Briers E(2016)Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers Futur Oncol. 12 333-342

[5] Cumberbatch MG(2016)11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel Eur J Nucl Med Mol Imaging. 43 84-91

[6] De Santis M(2017)Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients Eur J Nucl Med Mol Imaging 44 1258-1268

[7] Ceci F(2018)Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls RadioGraphics. 38 200-217

[8] Herrmann K(2018)68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients Eur J Nucl Med Mol Imaging 45 2035-2044

[9] Hadaschik B(2019)Diagnostic performance of 68Ga-PSMA PET/CT in the detection of prostate cancer prior to initial biopsy: comparison with cancer-predicting nomograms Eur J Nucl Med Mol Imaging 46 908-920

[10] Castellucci P(2017)Oligometastases in prostate cancer Strahlentherapie und Onkologie 194 318-324